Table 3.

Key cost, cost-effectiveness, health gain, and budget impact results by scenario

	Zambia		South Africa
	PopART 2014–30	PopART 2014–17	PopART 2014–30	PopART 2014–17
Cost
Mean cost per person per year during the trial period*	$6·53 (0·29)	$6·53 (0·29)	$7·93 (0·16)	$7·93 (0·16)
Cost-effectiveness
ICER: cost per HIV infection averted	$2111 (1827–2462)	$1318 (1098–1591)	$3248 (2472–3963)	$2236 (1601–2916)
ICER: cost per DALY averted	$593 (526–674)	$258 (225–298)	$645 (538–757)	$326 (266–391)
Health gains and budget impact
Annual cost of PopART during the trial period (undiscounted)	$3·98 million (2014), $4·44 million (2015), $4·58 million (2016), $4·88 million (2017)	$3·98 million (2014), $4·44 million (2015), $4·58 million (2016), $4·88 million (2017)	$2·61 million (2014), $3·10 million (2015), $3·17 million (2016), $3·25 million (2017)	$2·61 million (2014), $3·10 million (2015), $3·17 million (2016), $3·25 million (2017)
Incremental cost (undiscounted)	$46·12 million (115·0%)	$12·67 million (31·8%)	$30·24 million (118·2%)	$9·89 million (38·7%)
Incremental HIV infections averted (undiscounted)	22 769 (48·7%)	11 110 (23·7%)	9805 (38·6%)	5026 (19·8%)
Incremental DALYs averted (undiscounted)	86 413 (39·8%)	64 305 (29·6%)	52 961 (39·5%)	39 239 (29·2%)

Costs are expressed in 2017 US$. ICERs are the median and 95% credible intervals for 1000 simulations. Other data are presented as the mean (SD) or absolute value (percentage of counterfactual standard care). Incremental values represent the difference between the intervention compared with counterfactual simulations. ICER=incremental cost-effectiveness ratio. DALY=disability-adjusted life-year.

^*Includes home-based HIV counselling and testing, linkage to care, promotion of antiretroviral therapy adherence, and voluntary medical male circumcision, delivered by community HIV care providers to the population older than 14 years.